You don't have or don't remember the password! Click Here
Editor-in-chief
Maria Stella Graziani
Deputy Director
Martina Zaninotto
Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali
EIC Assistant
Francesco Busardò
International Advisory Board
Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada
Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano
Responsible Editor
Giuseppe Agosta
Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it
--------------------
ISSN print: 0393 – 0564
ISSN digital: 0392- 7091
BC: Articoli scritti da A. Gabutti
Analytical and clinical evaluation of the chemiluminescent microparticle immunoassay for galectin-3 determination
<p>This study tested if the chemiluminescent microparticle immunoassay (CMIA) method on the Architect platform meets the analytical and clinical quality goals required for the galectin-3 (GAL-3) use in clinical practice. We evaluated results obtained from 121 apparently healthy adults and 382 patients with heart failure (HF). All healthy subjects and patients showed GAL-3 concentrations in plasma above the limit of detection (1.9 μg/L) and the limit of quantitation (2.4 μg/L). GAL-3 in healthy subjects ranged between 6.4 and 40.6 μg/L (median, 13.0 μg/L, interquartile range, 11.2-15.2 μg/L, 97.5th percentile, 33.7 μg/L). GAL-3 values were found significantly increased in patients with chronic HF (median, 15.1 μg/L, interquartile range, 11.7-19.4 μg/L) compared to healthy subjects (P <0.0001). HF patients with cardiac fibrosis, confirmed by magnetic resonance, showed significantly higher GAL-3 values (median, 15.3 μg/L, interquartile range, 11.2-21.9 μg/L) than those without cardiac fibrosis (median, 12.9 μg/L, interquartile range, 11.2-15.0 μg/L) (P=0.03). ROC analysis showed that GAL-3 discriminates the presence of cardiac fibrosis with an area under the curve of 0.635 (0.526-0.744), with a specificity of 76.7% and a sensitivity of 54.1% at the cut-off of 14.6 μg/L. Using multivariable models cardiac fibrosis was significantly associated with the logGAL-3.</p>
Gentile utente, le ricordiamo che l'accesso alla rivista è riservato ai soci SIBioC in regola con la quota associativa.
Per accedere alla pagina richiesta è necessario inserire il suo nome utente e la password nella sezione "AREA SOCI".
A disposizione per ulteriori informazioni.
La Segreteria SIBioC
Dear User, please note that access to the Journal is for SIBioC members who have renewed their membership fee.
To access the requested page you need to enter username and password in "Area Soci".
At your disposal for further information.
SIBioC Secretariat